Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry - Calvo-Gutiérrez, Jerusalem; López-Medina, Clementina; Otero-Varela, Lucía; Escudero-Contreras, Alejandro; Ortega-Castro, Rafaela; Ladehesa-Pineda, Lourdes; Campos, Cristina; Bernabeu-Gonzalvez, Pilar; Pérez-Gómez, Ana; García-Dorta, Alicia; Ruiz-Montesino, Dolores; Pombo-Suarez, Manuel; et al. (Arthritis research & therapy, 2024)
Keywords: Antirheumatic agents; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; bDMARDs; Biological Products - therapeutic use; Chronic illnesses; Chronic obstructive pulmonary disease; Comorbidities; Comorbidity; Complications and side effects; Connective tissue diseases; Drug therapy; Fibromyalgia; Follow-Up Studies; Humans; Kinases; Medicine; Medicine & Public Health; Multimorbidity; Orthopedics; Patient compliance; Patient outcomes; Patients; Quality of life; Registries; Remission (Medicine); Retention; Rheumatic diseases; Rheumatoid arthritis; Rheumatology; Statistics; TNF inhibitors; Tumor necrosis factor-TNF; Variables; Spain; Comorbidities; Rheumatoid arthritis; bDMARDs